Poor prognosis acute myelogenous leukemia: 1 - Response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine)

Leukemia Research

Volumn 24, Issue 8, 2000, Pages 671-680

  Preisler, Harvey D ^a   Venugopal, Parameswaran ^a   Gregory, S A ^a   Hsu, Wei Tong ^a   Loew, Jerome ^a   Adler, Solomon ^a   Gezer, Sefer ^a   Creech, Steve ^a   Galvez, Angel ^a   Slivnick, David ^a   Andric, Tanja ^a   Larson, Richard A ^a   Jajeh, Ahmad ^a  

^a RUSH CANCER INSTITUTE   (United States)

Author keywords

Regrowth resistance; Suppression of telomerase activity

Indexed keywords

AMIFOSTINE; CYTARABINE; MITOXANTRONE; TELOMERASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW CELL; CARDIOVASCULAR DISEASE; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HYBRIDIZATION; KARYOTYPE; MALE; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RESPIRATORY FAILURE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; MITOXANTRONE; PILOT PROJECTS; PROGNOSIS; RADIATION-PROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 0033929972     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00037-0     Document Type: Article

References (34)

1. Preisler H.D., Lyman G.H. Acute myelogenous leukemia subsequent to therapy for a different neoplasm: clinical features and response to therapy. Am. J. Haematol. 3:1977;209.
2. Preisler H.D. Failure of remission induction in acute myelocytic leukemia. Med. Pediatr. Oncol. 4:1978;275.
3. Preisler H.D. Treatment failure in AML. Blood Cells. 8:1982;585.
4. Gajewski J.L., Ho W.G., Nimer S.D., Hirji K.F., Gekelman L., Jacobs A.D. et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J. Clin. Oncol. 7:1989;1637.
5. Hoyle C.F., deBastos M., Wheatley K., Sherrington P.D., Fischer P.J., Rees J.K. et al. AML associated with previous cytotoxic therapy, MDS, or myeloproliferative disorders: results from the MRC's 9th AML trial. Br. J. Haematol. 72:1989;45-53.
6. Kahn S.B., Begg C.B., Mazza J.J., Bennett J.M., Bonner H., Glick J.H. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J. Clin. Oncol. 2:1984;865.
7. Yates J., Glidewell O., Wiernik P., Cooper M.R., Steinberg D., Dosik H. et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 60:1982;454.
8. Preisler H.D., David R.B., Kirshner J., Dupre E., Richards F.D., Hoagland H.C. et al. Comparison of three remission induction regimens and the two post-induction strategies for the treatment of ANLL. A CALGB study. Blood. 69:1987;1441.
9. 1 transcript levels as an indication of resistant disease in acute nonlymphocytic leukemia. Br. J. Haematol. 75:1990;340-345.
10. Preisler H.D., Raza A., Sigmund D., Venugopal P. Poor prognosis acute myelogenous leukemia. Leuk. Lymph. 9:1993;273-283.
11. Taylor C.W., Dalton W.S., Parrish P.R., Gleason M.C., Bellamy W.T., Thompson F.H. et al. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br. J. Cancer. 63:1991;923.
12. Preisler HD, Li B, Yang J, Huang RW, Devemy E, Venugopal P, et al. Suppression of telomerase activity, and cytokine mRNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and IL-4, Clin Cancer Res 1999 (in press).
13. Li B, Yang J, Tao M, Nayini J, Horvath E, Chopra H, et al. Poor prognosis acute myelogenous leukemia: 2 - Biological and molecular biological features, Leuk. Res. 1999 (submitted).
14. Devemy E, Li B, Tao M, Yang J, Horvaath E, Fisher L, et al. Leukemia: 3 - Poor prognosis acute myelogenous leukemia: Biological and molecular biological changes during remission induction therapy, Blood 1999 (submitted).
15. Preisler H.D., Raza A., Barcos M., Azarnia N., Larson R., Walker I. et al. High dose cytosine arabinoside as the initial treatment of poor risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup study. J. Clin. Oncol. 5:1987;75.
16. Preisler H.D., Larson R.A., Raza A., Browman G., Goldberg J., Vogler R. et al. The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukemia: response to treatment and treatment failure. Br. J. Haematol. 79:1991;390.
17. Anderlini P., Luna M., Kantarjian H.M., O'Brien S., Pierce S., Keating M.J. et al. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 10:1996;600.
18. Fourth International Workshop in Leukemia: A prospective study of acute nonlymphocytic leukemia. Cancer Genet. Cytogenet. 1984;11:249.
19. Marchetti A., Buttitta F., Merlo G., Diella F., Pellegrini S., Pepe S. et al. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res. 15:1993;2846-2851.
20. Stratton M.R., Fisher C., Gusterson B.A., Copper C.S. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res. 15;49(22):1989;6324-6327.
21. Springall F., O'Mara S., Shounan Y., Todd A., Ford D. c-fms point mutations in acute myeloid leukemia: fact or fiction? Leukemia. 7(7):1993;978-985.
22. Li B, Horvath E, Chen H, Yang J, Larson A, Chen Y, et al. Study on unequal template-oligonucleotide duplexes by FMS site-directed mutation model for quantitative assay, Mol Cell Biol 1999 (submitted).
23. Gale R.E., Mein C.A., Linch D.C. Quantification of X-chromosome inactivation patters in haematological samples using DNA PCR-based HUMARA assay. Leukemia. 10:1996;362-367.
24. Preisler H.D., Yang J., Li B. Reduction of telomerase activity, cytokine production, and proliferative rate of AML cells in vivo in patients by the administration of amifostine or IL-4. Proc. Am. Soc. Clin. Oncol. 17 (abstract)(5a):1998;17.
25. Gao X.-Z., Chopra H., Huang X.-K., Preisler H.D. The effects of amifostine (AM) on myelodysplastic and myeloid leukemia progenitor cells. Proc. Am. Assoc. Cancer Res. #323. 38:1997;2164.
26. Chiu C.-P., Dragowska W., Kim N.-W., Vaziri H., Yui J., Thomas T.E. et al. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells. 14:1996;239-248.
27. Morrison S.J., Prowse K.R., Ho P., Weissman I.L. Telomerase activity in hematopoietic cells associated with self-renewal potential. Immunity. 5:1996;207-216.
28. Oster W., Cicco N.A., Klein H. Participation of the cytokines interleukin-6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous: leukemia blasts in autocrine and paracrine leukemia growth control. J. Clin. Invest. 84:1989;451-457.
29. Enschede SH, Shahidi H, Riley MB, Venugopal P, Jajeh A, Preisler HD, Gregory SA. Lack of severe toxicity of interferon-alpha (IFN-α) added to an anthracyclin-based regimen in treating low grade (LG) and intermediate grade (IG) non-Hodgkins' lymphoma (NHL). B cell lymphoproliferative disorders. Contributions of molecular and cell biology to understanding and treatment. Presentation Summaries and Abstracts, New York, New York #72, 1998. Presented before the symposium B-Cell Lymphoproliferative Disorders: Contributions of Molecular and Cell Biology to Understanding and Treatment, New York, New York, April 18-21, 1998 (poster).
30. Preisler H.D. Fitness landscapes and the myeloid leukemia. Leuk. Res. 23:1999;167-176.
31. Fialkow F.J., Singer J., Raskind W.H. Clonal development, stem cell differentiation and the nature of clinical remission in acute nonlymphocytic leukemia: studies of patients heterozygous for glucose-6-dehydrogenase. New Engl. J. Med. 317:1987;1415-1417.
32. Fialkow F.J., Jannsen J.W.G., Bartram C.R. Clonal remission in acute nonlymphocytic leukemia: evidence for a multistep pathogenesis of the malignancy. Blood. 77:1991;1413-1417.
33. Preisler H.D., Barcos M., Reese P., Priore R.L., Pothier L. Recognition of drug resistance during remission induction therapy for acute nonlymphocytic leukemia: utility of day 6 bone marrow biopsy. Leuk. Res. 7:1983;67-75.
34. Preisler H.D., Epstein J., Barcos M., Priore R., Browman G., Vogler R. et al. Prediction of response of acute nonlymphocytic leukemia to therapy with 'high dose' cytosine arabinoside. Br. J. Haematol. 58:1984;19-32.